← Human Trials & Peer-Reviewed Studies
Effects of vitamin K2 supplementation on atherogenic status of individuals with type 2 diabetes: a randomized controlled trial
Plain-language guide to PMID 33933059 (2021): double-blind randomized controlled trial study of Vitamin D, K2, Magnesium and Zinc in 68 patients.
Key Facts
- PMID
- 33933059
- Journal
- BMC complementary medicine and therapies
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Rahimi Sakak F et al. (4 authors)
- DOI
- 10.1186/s12906-021-03304-3
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
This study was aimed to examine the effects of vitamin K2 supplementation on atherogenic status, assessed by insulin resistance (IR)-related indexes, in patients with type 2 diabetes mellitus (T2DM).
Why It Was Studied
The trial was registered on Iranian Registry of Clinical Trials registry (Trial ID.
IRCT20190824044592N1) on 22 December 2019.
Who Took Part
The study group was 68 patients.
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.
Eight different IR-related indexes were calculated at the baseline and end of the trial.
What Was Measured
The subject headings attached to it are Atherosclerosis, Diabetes Mellitus, Type 2, Insulin Resistance, Lipids and Vitamin K 2.
Author keywords: Atherogenic index, Atherogenic status, Cardiovascular diseases, Menaquinone-7 and Type 2 diabetes.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 68 patients.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2021 (BMC complementary medicine and therapies), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.